

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.:
L74899DL1998PLC056594
Date: 24.02.2021

Ref: STEX/BSE/2020-21

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

Company No: 531146

Re: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Subject: Plant Visit by analysts/Investors.

Dear Sir(s)/ Madam,

In terms of Regulation 30 read with Para A of Part A of Schedule III to the Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that on Thursday, February 25, 2021, the following group of analysts/ investors (“Investors”), shall be visiting our new state of art FDA USA compliant Pharma Oncology Manufacturing Plant at Haridwar, which is already commissioned.

S. No.	Investor's Name	Group
1.	Monic Shah	Investburg
2.	Ashish Chugh	Individual Investor
3.	Mohit Jangir	Individual Investor
4.	Nav Rattan Bhaiya	Tetris Capital Venture
5.	Ayush Gupta	SA Investment Advisors
6.	Aniket Gore	Individual Investor
7.	Sandeep Bhandari	Individual Investor

This is for your information and records.

Thanking You

Yours truly,
For Medicamen Biotech Limited



Parul Choudhary
Company Secretary & Compliance Officer
ACS: 44157